Flashpoint Therapeutics Appoints Barry Labinger as CEO

Flashpoint Therapeutics, a clinical-stage biotechnology company developing precision-engineered structural nanomedicines, appointed Barry Labinger as Chief Executive Officer. 

Labinger joins Flashpoint at a time when the company aims to advance its scientific platform toward key clinical milestones.

With over three decades of executive experience in the biopharmaceutical industry, Labinger brings a track record of building and leading innovative life sciences organizations through critical phases of growth, development, and commercialization.

Labinger most recently served as President and CEO of Gilboa Therapeutics, where he led the development of a novel engineered T-cell platform for solid tumors. Before Gilboa, Labinger served as CEO at Checkmate Pharmaceuticals, where he led the company’s IPO and advanced its lead clinical cancer immunotherapy program into registrational trials. 

During his previous leadership positions at Human Genome Sciences, Bristol Myers Squibb, and Abbott Laboratories, Labinger established and led major collaborations with industry leaders and helped bring groundbreaking therapies to patients.

“We are delighted to welcome Barry Labinger to Flashpoint. His track record and deep experience in the strategic, scientific, clinical, and commercial aspects of innovative therapeutics companies make him the ideal CEO to lead the next stage of growth for our company and the application of our technology to address major patient needs,” said Dr. Chad Mirkin, Co-Founder and Member of the Flashpoint Therapeutics Board of Directors.

“I am thrilled to join Flashpoint Therapeutics at this critical juncture. Its structural nanomedicine platform is built upon extraordinary science developed at the laboratories of Dr. Chad Mirkin at Northwestern University, and I am confident it will result in groundbreaking new therapies that will make a profound impact on patients’ lives,” said Barry Labinger, CEO of Flashpoint Therapeutics.